Interleukin-10 Production during Septic Shock

  • M. Goldman
  • A. Marchant
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1996)


Human interleukin (IL)-10 is a protein of 160 amino acids (molecular weight: 18.5 kDa) containing two intramolecular disulfide bonds [1, 2]. It is acid-labile and appears in soluble form as a homodimer. The gene encoding IL-10, which is located on chromosome 1 both in mouse and man, contains several noncoding sequences which are thought to control its transcription and the stability of the corresponding mRNA [3]. Several cell types can produce IL-10 including CD4+ and CD8+ T cells, macrophages/monocytes, B cells, keratinocytes, mesangial cells and a variety of tumor cells [1]. In most inflammatory disorders including septic shock, cells of the monocytic lineage represent the major source of IL-10.


Tumor Necrosis Factor Septic Shock Mycobacterium Avium Staphylococcal Enterotoxin Listeria Meningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11: 165–190PubMedCrossRefGoogle Scholar
  2. 2.
    Windsor WT, Syto R, Tsarbopoulos A, et al (1993) Disulfide bond assignments and secondary structure analysis of human and murine interleukin-10. Biochemistry 32: 8807–8815PubMedCrossRefGoogle Scholar
  3. 3.
    Kim JM, Brannan CI, Copeland NG, Jenkins NA, Khan TA, Moore KW (1992) Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol 148: 3618–3623PubMedGoogle Scholar
  4. 4.
    Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G (1993) Interleukin-10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178: 2207–2211PubMedCrossRefGoogle Scholar
  5. 5.
    Takanaski S, Nonaka R, Xing Z, Obyrne P, Dolovich J, Jordana M (1994) Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 180: 711–715PubMedCrossRefGoogle Scholar
  6. 6.
    Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin-10. J Exp Med 174: 1549–1555PubMedCrossRefGoogle Scholar
  7. 7.
    Gazzinelli RT, Oswald IP, James SL, Sher A (1992) IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. J Immunol 148: 1792–1796PubMedGoogle Scholar
  8. 8.
    Cunha FQ, Moncada S, Liew FY (1992) Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-γ in murine macrophages. Biochem Biophys Res Commun 182: 1155–1159PubMedCrossRefGoogle Scholar
  9. 9.
    Mertz PM, Dewitt DL, Stetlerstevenson WG, Wahl LM (1994) Interleukin-10 suppression of monocyte prostaglandin H synthase-2: Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chern 269: 21322–21329Google Scholar
  10. 10.
    Niiro H, Otsuka T, Kuga S, et al (1994) IL-10 inhibits prostaglandin E(2) production by lipopolysaccharide-stimulated monocytes. Int Immunol 6: 661–664PubMedCrossRefGoogle Scholar
  11. 11.
    Pradier O, Gérard C, Delvaux A, et al (1993) Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 23: 2700–2703PubMedCrossRefGoogle Scholar
  12. 12.
    Jenkins JK, Malyak M, Arend WP (1994) The effects of interleukin-10 on interleukinreceptor antagonist and interleukin-1β production in human monocytes and neutrophils. Lymphokine Cytokine Res 13: 84–89Google Scholar
  13. 13.
    Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S (1994) Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 179: 1695–1699PubMedCrossRefGoogle Scholar
  14. 14.
    de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209–1220CrossRefGoogle Scholar
  15. 15.
    Khün R, Löhler J, Rennick D, Rajewsky K, Müller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274CrossRefGoogle Scholar
  16. 16.
    Gérard C, Bruyns C, Marchant A, et al (1993) Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547–550PubMedCrossRefGoogle Scholar
  17. 17.
    Marchant A, Bruyns C, Vandenabeele P, et al (1994) Interleukin-10 controls interferon γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24: 1167–1171PubMedCrossRefGoogle Scholar
  18. 18.
    Howard M, Muchamuel T, Andrade S, Menon S (1993) Interleukin 10 protects mice from lethal en do toxemia. J Exp Med 177: 1205–1208PubMedCrossRefGoogle Scholar
  19. 19.
    Bean AGD, Freiberg RA, Andrade S, Menon S, Zlotnik A (1993) Interleukin-10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immunol 61: 4937–4939Google Scholar
  20. 20.
    Bermudez LE, Champsi J (1993) Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immunol 61: 3093–3097Google Scholar
  21. 21.
    Denis M, Ghadirian E (1993) IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections. J Immunol 151: 5425–5430PubMedGoogle Scholar
  22. 22.
    Frei K, Nadal D, Pfister HW, Fontana A (1993) Listeria meningitis: Identification of a cerebrospinal fluid inhibitor of macrophage listericidal function as interleukin-10. J Exp Med 178: 1255–1261PubMedCrossRefGoogle Scholar
  23. 23.
    Durez P, Abramowicz D, Gerard C, et al (1993) In vivo induction of interleukin-10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: Differential modulation by cyclosporin A. J Exp Med 177: 551–555PubMedCrossRefGoogle Scholar
  24. 24.
    Marchant A, Vincent JL, Goldman M (1996) Interleukin-10 as a protective cytokine produced during sepsis. In: Morrison DC, Ryan JL (eds) Novel therapeutic strategies in the treatment of sepsis. Marcel Decker, New York, pp 301–311Google Scholar
  25. 25.
    Ishida H, Hastings R, Thompson-Snipes L, Howard M (1993) Modified immunological status of anti-IL-10 treated mice. Cell Immunol 148: 371–384PubMedCrossRefGoogle Scholar
  26. 26.
    van der Poll T, Marchant A, Buurman W, et al (1996) Endogenous interleukin-10 protects mice from death during septic peritonitis. J Immunol (In press)Google Scholar
  27. 27.
    Zanetti G, Heumann D, Gerain J, et al (1992) Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 148: 1890–1897PubMedGoogle Scholar
  28. 28.
    Florquin S, Amraoui Z, Abramowicz D, Goldman M (1994) Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol 153: 2618–2623PubMedGoogle Scholar
  29. 29.
    Marchant A, Devière J, Byl B, De Groote D, Vincent JL, Goldman M (1994) Interleukin-10 production during septicaemia. Lancet 343: 707–708PubMedCrossRefGoogle Scholar
  30. 30.
    Marchant A, Alegre ML, Hakim A, et al (1996) Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol (In press)Google Scholar
  31. 31.
    Chernoff AE, Granowitz EV, Shapiro L, et al (1995) A randomized, controlled trial of IL-10 in humans: Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492–5499PubMedGoogle Scholar
  32. 32.
    Platzer C, Meisel C, Vogt K, Platzer M, Yolk HD (1995) Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int Immunol 7: 517–523PubMedCrossRefGoogle Scholar
  33. 33.
    Strassmann G, Patilkoota V, Finkelman F, Fong M, Kambayashi T (1994) Evidence for the involvement of interleukin-10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E(2). J Exp Med 180: 2365–2370PubMedCrossRefGoogle Scholar
  34. 34.
    Mengozzi M, Fantuzzi G, Faggioni R, et al (1994) Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice. Immunology 82: 207–210PubMedGoogle Scholar
  35. 35.
    Tarazona R, Gonzalezgarcia A, Zamzami N, et al (1995) Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 154: 861–870PubMedGoogle Scholar
  36. 36.
    Ianaro A, O’Donnell CA, DiRosa M, Liew FY (1994) A nitric oxide inhibitor reduces inflammation, down-regulates inflammatory cytokines and enhances interleukin-10 production in carrageenin-induced edema in mice. Immunology 82: 370–375PubMedGoogle Scholar
  37. 37.
    Bourrie B, Bouaboula, Benoit JM, Derocq JM, Esclangon M, Casellas P (1995) Enhancement of endotoxin-induced anti-inflammatory cytokine IL10 production by the sigma ligand SR31747. 9th International Congress of Immunology, San Francisco: 897 (Abst)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Goldman
  • A. Marchant

There are no affiliations available

Personalised recommendations